Effectiveness of Digital Therapeutics to Improve Blood Pressure Control Among Patients With Hypertension and Diabetes in India

Adhikary, Rishi; Krishnakumar, Arjun; Kolwankar, Siddhesh; Shah, Abhishek; Sanghavi, Snehal T; Mattoo, Vinod

doi:10.1016/s0735-1097(20)34210-8

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with T2D, the use of a 16-week structured self-management program delivered with the WC mobile application showed improved glycemic control, weight reduction, and self-management ( 15 , 16 ). In patients with T2D and hypertension previously using WC for their diabetes management, the addition of hypertension self-management education and self-reported blood pressure (BP) measures showed that the platform facilitated glycemic control while achieving a significant reduction in BP ( 17 ). Lastly, a study assessing the WC platform performance during the COVID-19 lockdown showed similar decreases in average blood glucose to those observed in the pre-lockdown despite increased ePROs ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

Peñate

Parra

Morera

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

IntroductionPulmonary arterial hypertension (PAH) is a rare, multifactorial, chronic condition that requires ongoing monitoring and assessment. PAHcare™ is a novel, patient-centered digital platform that provides software intended for use on patients' mobile phones (downloadable application) and web-based dashboards for use by physicians and health coaches (HC). We describe herein the protocol of a clinical study aimed at evaluating the clinical benefit and safety of PAHcare™ for the routine management of patients with PAH.Methods and analysisIn this prospective, single cohort, multicenter study, 50 patients with PAH will be recruited at six specialized PAH units from reference hospitals of the public Spanish healthcare system. The PAHcare™ digital health platform allows patients to log health and lifestyle information while also providing structured content for patient education, medication reminders, and behavioral and lifestyle coaching from a remote HC. Evaluation will be primarily focused on the impact of the platform use on the patient's health-related quality of life (HRQoL) via questionnaires completion through electronic patient-reported outcomes. Moreover, the analysis of the impact on the patient's functional status, signs and symptoms of PAH, patient costs and healthcare resource utilization, satisfaction, knowledge of the disease and its management, and adherence to and safety of the platform will be secondary outcomes. The clinical investigation started in July 2021 and is expected to end by September 2022.DiscussionThe PAHcare™ platform is anticipated to provide direct benefits to healthcare professionals, patients, and caregivers. These include the simplification of the multidisciplinary approach needed to tailor routine PAH management, enhancement of the patient/healthcare professional interaction, patient's empowerment to become more actively involved in the management and treatment of the disease, and increase of the patient's and caregiver's knowledge on PAH.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

Peñate

Parra

Morera

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Sharma

2023

CHYR

View full text Add to dashboard Cite

Hypertension is a significant hazardous aspect for several diseases, like cardiovascular disease, kidney failure, and brain disease. Hypertension has become the most lethal condition globally, affecting approximately 1 billion people aged around 30-79 years worldwide. In the year 2022, India was ranked 170th for men and 193rd for women for HTN diagnosis rates among 200 countries worldwide. The main risk factor for cardiac failure and stroke is hypertension. The conventional classes of antihypertensive medications currently available have some side effects. Previously, hypertension has been discussed by various researchers using conventional drug-targeting methods such as ACE inhibitors, aldosterone inhibitors, or renin inhibitors. Recently, novel drug delivery technologies utilizing nanoparticles and new pharmacological classes like ACE2 and APA inhibitors have been studied for the medication of hypertension. In this review, we have covered the epidemiology of hypertension in India, its pathophysiology, medications used in the management of hypertension using nanotechnology, and antihypertensive drugs currently available in the market that are approved and patented. Finally, we have covered how hypertension can be managed with the help of smart devices and artificial intelligence (AI) for improved therapy.

show abstract

Effectiveness of Digital Therapeutics to Improve Blood Pressure Control Among Patients With Hypertension and Diabetes in India

Cited by 2 publications

References 0 publications

Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Contact Info

Product

Resources

About